跳至主要内容
临床试验/NCT01340053
NCT01340053已完成2 期

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Ardelyx1 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Ardelyx
入组人数
186
试验地点
1
主要终点
Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline

研究概览

简要总结

This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery of screening procedures to determine eligibility for the trial.

The study will consist of a 2-week treatment-free screening period, a 4-week blinded treatment period, and a 2-week treatment-free follow-up period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject meets Rome III criteria for IBS-C
  • If > 50 years old, colonoscopy evaluation within 10 years
  • All ages, negative colonoscopy if any "warning symptoms"
  • Active disease during 2-week screening period
  • Compliant with IVRS

排除标准

  • Subjects has IBS-D, IBS-M or un-subtyped IBS according to Rome III criteria
  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract
  • Use of medications that are known to affect stool consistency
  • Subject has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments or prevent completion of study

研究组 & 干预措施

Placebo

Placebo Comparator

Capsule that is identical in size and color to other treatments

干预措施: RDX5791 (Drug)

Low Dose

Experimental

10 mg capsule of tenapanor

干预措施: RDX5791 (Drug)

Mid Dose

Experimental

30 mg capsule of tenapanor

干预措施: RDX5791 (Drug)

High Dose

Experimental

100 mg capsule of tenapanor

干预措施: RDX5791 (Drug)

结局指标

主要结局

Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline

时间窗: Baseline and Week 4

Patients complete a phone diary daily. They are asked "how many bowel movements have you had today?" they are then asked for each spontaneous bowel movement (unaided with laxative use) wether there was its was a complete evacuation. if it was then it is a complete spontaneous bowel movement. All CSBMs are added and adjusted for a mean compete sponteneous bowel movement.

次要结局

  • Spontaneous Bowel Movement (SBM) Frequency Change From Baseline(baseline and week 4)

研究者

发起方
Ardelyx
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验